학술논문
Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations (Nature Cancer, (2023), 4, 9, (1345-1361), 10.1038/s43018-023-00630-y)
Document Type
Erratum
Author
Miyazaki, I.; Ishida, K.; Kato, M.; Suzuki, T.; Wakayama, K.; Fujita, H.; Yamada, Y.; Funabashi, K.; Ohkubo, S.; Yano, W.; Terada, R.; Iwasawa, Y.; Odintsov, I.; Lui, A.J.W.; Zhang, T.; Kurth, R.I.; Cheng, R.; Delasos, L.; Vojnic, M.; Mattar, M.S.; Lu, Y.C.; Kunte, S.; Ladanyi, M.; Somwar, R.; Ishizawa, K.; Cheng, E.H.; Khodos, I.; Chang, Q.; de Stanchina, E.; Giuliano, C.; Bonifacio, A.; Lovati, E.; Davare, M.A.
Source
In: Nature Cancer . (Nature Cancer, October 2023, 4(10):1526)
Subject
Language
English
ISSN
26621347